Compare Stocks → Urgent: Protect Your Investments from a Chinese Invasion (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADXNNASDAQ:ALRNNASDAQ:KZIANASDAQ:VYNE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$12.80+3.6%$10.48$5.00▼$23.40$12.67M1.629,729 shs3,314 shsALRNAileron Therapeutics$6.75-2.6%$5.01$1.01▼$7.12$33.01M2.1938,660 shs13,002 shsKZIAKazia Therapeutics$0.31-1.2%$0.28$0.19▼$1.68$5.06M2.09834,807 shs307,328 shsVYNEVYNE Therapeutics$3.00+1.4%$2.13$1.67▼$8.73$42.30M1.18126,168 shs148,883 shs7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics+0.08%+1.23%+19.90%+110.03%-45.35%ALRNAileron Therapeutics+22.66%+28.91%+51.50%+122.96%+445.38%KZIAKazia Therapeutics-0.60%+12.44%+5.69%-30.29%-68.31%VYNEVYNE Therapeutics+4.59%+35.78%+25.96%+18.40%+12.55%Only a fool would buy Nvidia today… (Ad)Average people are too busy throwing their money into Nvidia, Google, and every other overvalued tech firm… while missing what could be the biggest story of the decade.In this new presentation – which Porter Stansberry details why this company could be the linchpin ofMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics0.2232 of 5 stars0.03.00.00.01.90.80.6ALRNAileron Therapeutics3.4841 of 5 stars3.55.00.00.03.91.70.6KZIAKazia Therapeutics3.1704 of 5 stars3.55.00.00.03.20.01.3VYNEVYNE Therapeutics3.807 of 5 stars3.55.00.00.03.91.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics2.00HoldN/AN/AALRNAileron Therapeutics3.00Buy$9.0033.33% UpsideKZIAKazia Therapeutics3.00Buy$2.00545.58% UpsideVYNEVYNE Therapeutics3.00Buy$7.38145.83% UpsideCurrent Analyst RatingsLatest KZIA, VYNE, ALRN, and ADXN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/29/2024VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.75(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$1.51M8.39N/AN/A$8.01 per share1.60ALRNAileron TherapeuticsN/AN/AN/AN/A$4.10 per shareN/AKZIAKazia Therapeutics$20K253.11N/AN/A$0.50 per share0.62VYNEVYNE Therapeutics$420K100.71N/AN/A$6.36 per share0.47Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics-$21.80M-$19.27N/AN/AN/A-550.78%-236.83%-147.15%4/4/2024 (Estimated)ALRNAileron Therapeutics-$27.33MN/A0.00N/AN/AN/A-83.80%-72.25%4/1/2024 (Estimated)KZIAKazia Therapeutics-$13.78MN/A0.00N/AN/AN/AN/AN/AN/AVYNEVYNE Therapeutics-$28.45M-$7.04N/AN/AN/A-6,710.38%-77.46%-62.93%5/9/2024 (Estimated)Latest KZIA, VYNE, ALRN, and ADXN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/29/2024Q4 2023VYNEVYNE Therapeutics-$0.50-$0.20+$0.30-$0.20$0.15 million$0.08 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/AALRNAileron TherapeuticsN/AN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A2.972.97ALRNAileron TherapeuticsN/A7.887.88KZIAKazia TherapeuticsN/A1.421.42VYNEVYNE TherapeuticsN/A12.7312.73OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%ALRNAileron Therapeutics90.89%KZIAKazia Therapeutics30.89%VYNEVYNE Therapeutics83.78%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%ALRNAileron Therapeutics5.57%KZIAKazia Therapeutics1.00%VYNEVYNE Therapeutics1.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics24990,000843,000Not OptionableALRNAileron Therapeutics64.89 million4.61 millionNot OptionableKZIAKazia Therapeutics2,02116.34 million16.18 millionOptionableVYNEVYNE Therapeutics1014.10 million13.85 millionNot OptionableKZIA, VYNE, ALRN, and ADXN HeadlinesSourceHeadlineAcne Treatment Market Poised for Substantial Growth, Anticipated to Reach USD 16.2 Billion by 2032pharmiweb.com - March 28 at 12:46 PMVYNE Therapeutics (NASDAQ:VYNE) Stock Price Up 3.9%americanbankingnews.com - March 23 at 1:48 AMVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conferencefinance.yahoo.com - March 19 at 9:08 AMVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conferenceglobenewswire.com - March 19 at 8:00 AMHere's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Nowzacks.com - March 13 at 10:56 AMWhat Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stockzacks.com - March 8 at 1:01 PMWall Street Breakfast Podcast: NYCB Gets $1B Investment Boostseekingalpha.com - March 7 at 8:21 AMVYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lagfinance.yahoo.com - March 3 at 8:59 AMBuy Rating on VYNE Therapeutics: Strong Financials and Promising Clinical Developmentsmarkets.businessinsider.com - February 29 at 7:00 PMVYNE Therapeutics Inc.: VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Updatefinanznachrichten.de - February 29 at 10:04 AMVYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Updateglobenewswire.com - February 29 at 8:00 AMVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposiumfinance.yahoo.com - February 27 at 8:06 AMVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposiumglobenewswire.com - February 27 at 8:00 AMVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conferencefinance.yahoo.com - February 21 at 8:16 AMVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 21 at 8:00 AMFavourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stockfinance.yahoo.com - February 2 at 7:18 AMBuy Rating for VYNE Therapeutics Backed by Promising Vitiligo Drug Trial Resultsmarkets.businessinsider.com - January 10 at 4:27 PMPrurigo Nodularis Treatment Market Forecasts Surpassing US$ 930.9 Million by 2033-FMI Studyfmiblog.com - January 4 at 12:32 AMVYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directorsfinance.yahoo.com - January 3 at 9:29 AMInvesting in VYNE Therapeutics Inc [VYNE]: What You Must Knowknoxdaily.com - January 1 at 10:15 AMVYNE Therapeutics says director Lepore buys 13K shares in comsn.com - November 20 at 3:25 PMCormorant Asset Management, LP Acquires New Stake in VYNE Therapeutics Incfinance.yahoo.com - November 14 at 5:53 PMVYNE Therapeutics files to sell 36.27M shares for holdersmsn.com - November 13 at 5:35 PMVYNE Therapeutics Inc.: VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updatefinanznachrichten.de - November 13 at 12:34 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAddex TherapeuticsNASDAQ:ADXNAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Aileron TherapeuticsNASDAQ:ALRNAileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.Kazia TherapeuticsNASDAQ:KZIAKazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.VYNE TherapeuticsNASDAQ:VYNEVYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor for the treatment of immuno-inflammatory indications; and FMX114, a combination gel formation of tofacitinib and fingolimod, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.